Indeed, the combination of the programmed death ligand 1 (PD-L1) immune checkpoint inhibitor atezolizumab and the monoclonal anti-VEGF antibody bevacizumab is considered standard of care for unresectable HCC following the analysis of the IMbrave150 study and subsequent FDA approval for this indication [80,81]. Here, CD274 is linked to hepatocellular carcinoma.